Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) Equity Average (2021 - 2026)

HeartSciences (HSCS) has disclosed Equity Average for 5 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 26.4% year-over-year to $3.7 million, compared with a TTM value of $3.7 million through Oct 2025, down 26.4%, and an annual FY2025 reading of $3.8 million, changed 0.34% over the prior year.
  • Equity Average was $3.7 million for Q4 2025 at HeartSciences, up from $1.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $8.0 million in Q2 2024 and bottomed at -$5.1 million in Q2 2022.
  • Average Equity Average over 5 years is $1.2 million, with a median of $995930.0 recorded in 2025.
  • The sharpest move saw Equity Average plummeted 154.65% in 2023, then skyrocketed 58411.6% in 2024.
  • Year by year, Equity Average stood at -$2.9 million in 2021, then soared by 167.86% to $2.0 million in 2022, then plummeted by 154.65% to -$1.1 million in 2023, then skyrocketed by 558.69% to $5.0 million in 2024, then fell by 26.4% to $3.7 million in 2025.
  • Business Quant data shows Equity Average for HSCS at $3.7 million in Q4 2025, $1.7 million in Q3 2025, and $995930.0 in Q2 2025.